Literature DB >> 11290466

Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens.

C Dowling1, A W Bollen, S M Noworolski, M W McDermott, N M Barbaro, M R Day, R G Henry, S M Chang, W P Dillon, S J Nelson, D B Vigneron.   

Abstract

BACKGROUND AND
PURPOSE: Tumor progression is often difficult to distinguish from nonneoplastic treatment response on the basis of MR images alone. This study correlates metabolite levels measured by preoperative MR spectroscopic (MRS) imaging with histologic findings of biopsies, obtained during image-guided resections of brain mass lesions, to clarify the potential role of MRS in making this distinction.
METHODS: Twenty-nine patients with brain tumors underwent high-resolution (0.2-1 cc) 3D proton MRS imaging and MR imaging before undergoing surgery; 11 had a newly diagnosed neoplasm, and 18 had recurrent disease. Surgical biopsies were obtained from locations referenced on MR images by guidance with a surgical navigation system. MR spectral voxels were retrospectively centered on each of 79 biopsy locations, and metabolite levels were correlated with histologic examination of each specimen.
RESULTS: All mass lesions studied, whether attributable to tumor or noncancerous effects of previous therapy, showed abnormal MR spectra compared with normal parenchyma. When the pattern of MRS metabolites consisted of abnormally increased choline and decreased N-acetyl aspartate (NAA) resonances, histologic findings of the biopsy specimen invariably was positive for tumor. When choline and NAA resonances were below the normal range, histologic findings were variable, ranging from radiation necrosis, astrogliosis, and macrophage infiltration to mixed tissues that contained some low-, intermediate-, and high-grade tumor.
CONCLUSION: This study demonstrated that 3D MRS imaging can identify regions of viable cancer, which may be valuable for guiding surgical biopsies and focal therapy. Regions manifesting abnormal MR spectra had a mixture of histologic findings, including astrogliosis, necrosis, and neoplasm.

Entities:  

Mesh:

Year:  2001        PMID: 11290466      PMCID: PMC7976037     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  59 in total

1.  Single-voxel proton brain spectroscopy exam (PROBE/SV) in patients with primary brain tumors.

Authors:  R D Tien; P H Lai; J S Smith; F Lazeyras
Journal:  AJR Am J Roentgenol       Date:  1996-07       Impact factor: 3.959

2.  Proton MR spectroscopy of the brain: clinically useful information obtained in assessing CNS diseases in children.

Authors:  Z Wang; R A Zimmerman; R Sauter
Journal:  AJR Am J Roentgenol       Date:  1996-07       Impact factor: 3.959

3.  Prediction of posterior fossa tumor type in children by means of magnetic resonance image properties, spectroscopy, and neural networks.

Authors:  J E Arle; C Morriss; Z J Wang; R A Zimmerman; P G Phillips; L N Sutton
Journal:  J Neurosurg       Date:  1997-05       Impact factor: 5.115

4.  Localized 1H NMR spectroscopy in fifty cases of newly diagnosed intracranial tumors.

Authors:  P Demaerel; K Johannik; P Van Hecke; C Van Ongeval; S Verellen; G Marchal; G Wilms; C Plets; J Goffin; F Van Calenbergh
Journal:  J Comput Assist Tomogr       Date:  1991 Jan-Feb       Impact factor: 1.826

5.  Radiation-induced changes in human brain metabolites as studied by 1H nuclear magnetic resonance spectroscopy in vivo.

Authors:  T Usenius; J P Usenius; M Tenhunen; P Vainio; R Johansson; S Soimakallio; R Kauppinen
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-10-15       Impact factor: 7.038

6.  Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies.

Authors:  M L Simmons; C G Frondoza; J T Coyle
Journal:  Neuroscience       Date:  1991       Impact factor: 3.590

7.  Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance.

Authors:  M J Fulham; A Bizzi; M J Dietz; H H Shih; R Raman; G S Sobering; J A Frank; A J Dwyer; J R Alger; G Di Chiro
Journal:  Radiology       Date:  1992-12       Impact factor: 11.105

8.  1H MR spectroscopy in patients with metastatic brain tumors: a multicenter study.

Authors:  P E Sijens; M V Knopp; A Brunetti; K Wicklow; B Alfano; P Bachert; J A Sanders; A E Stillman; H Kett; R Sauter
Journal:  Magn Reson Med       Date:  1995-06       Impact factor: 4.668

Review 9.  Magnetic resonance spectroscopy of tumors and potential in vivo clinical applications: a review.

Authors:  P F Daly; J S Cohen
Journal:  Cancer Res       Date:  1989-02-15       Impact factor: 12.701

10.  Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy.

Authors:  H Shimizu; T Kumabe; T Tominaga; T Kayama; K Hara; Y Ono; K Sato; N Arai; S Fujiwara; T Yoshimoto
Journal:  AJNR Am J Neuroradiol       Date:  1996-04       Impact factor: 3.825

View more
  99 in total

1.  In vivo characterization of several rodent glioma models by 1H MRS.

Authors:  Sabrina Doblas; Ting He; Debra Saunders; Jessica Hoyle; Nataliya Smith; Quentin Pye; Megan Lerner; Randy L Jensen; Rheal A Towner
Journal:  NMR Biomed       Date:  2011-09-23       Impact factor: 4.044

2.  The relationship between Cho/NAA and glioma metabolism: implementation for margin delineation of cerebral gliomas.

Authors:  Jun Guo; Chengjun Yao; Hong Chen; Dongxiao Zhuang; Weijun Tang; Guang Ren; Yin Wang; Jinsong Wu; Fengping Huang; Liangfu Zhou
Journal:  Acta Neurochir (Wien)       Date:  2012-06-23       Impact factor: 2.216

Review 3.  Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.

Authors:  Ovidiu C Andronesi; Otto Rapalino; Elizabeth Gerstner; Andrew Chi; Tracy T Batchelor; Dan P Cahill; A Gregory Sorensen; Bruce R Rosen
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

4.  Multisection 1H magnetic resonance spectroscopic imaging assessment of glioma response to chemotherapy.

Authors:  Casilda Balmaceda; Dana Critchell; Xiangling Mao; Kenneth Cheung; Susan Pannullo; Robert L DeLaPaz; Dikoma C Shungu
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

5.  Multiparametric 3T MR approach to the assessment of cerebral gliomas: tumor extent and malignancy.

Authors:  Alfonso Di Costanzo; Tommaso Scarabino; Francesca Trojsi; Giuseppe M Giannatempo; Teresa Popolizio; Domenico Catapano; Simona Bonavita; Nicola Maggialetti; Michela Tosetti; Ugo Salvolini; Vincenzo A d'Angelo; Giocchino Tedeschi
Journal:  Neuroradiology       Date:  2006-06-03       Impact factor: 2.804

Review 6.  Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making.

Authors:  Alexander Lin; Brian D Ross; Kent Harris; Willis Wong
Journal:  NeuroRx       Date:  2005-04

7.  Evaluation of invasiveness of astrocytoma using 1H-magnetic resonance spectroscopy: correlation with expression of matrix metalloproteinase-2.

Authors:  Kai Zhang; Chuanfu Li; Ying Liu; Li Li; Xiangxing Ma; Xiangshui Meng; Dechao Feng
Journal:  Neuroradiology       Date:  2007-09-01       Impact factor: 2.804

Review 8.  Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients.

Authors:  John H Rossmeisl; Paulo A Garcia; Gregory B Daniel; John Daniel Bourland; Waldemar Debinski; Nikolaos Dervisis; Shawna Klahn
Journal:  Vet Radiol Ultrasound       Date:  2013-11-13       Impact factor: 1.363

Review 9.  Techniques to assess the proliferative potential of brain tumors.

Authors:  Alfredo Quiñones-Hinojosa; Nader Sanai; Justin S Smith; Michael W McDermott
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

Review 10.  Clinical applications of metabolomics in oncology: a review.

Authors:  Jennifer L Spratlin; Natalie J Serkova; S Gail Eckhardt
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.